Generation Bio Co Stock EBITDA
| GBIO Stock | USD 1.37 0.05 3.79% |
Generation Bio Co fundamentals help investors to digest information that contributes to Generation Bio's financial success or failures. It also enables traders to predict the movement of Generation Stock. The fundamental analysis module provides a way to measure Generation Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Generation Bio stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -133.3 M | -140 M |
Generation | EBITDA |
Generation Bio Co Company EBITDA Analysis
Generation Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Generation Bio EBITDA | (133.3 M) |
Most of Generation Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Generation Bio Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generation EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Generation Bio is extremely important. It helps to project a fair market value of Generation Stock properly, considering its historical fundamentals such as EBITDA. Since Generation Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Generation Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Generation Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Generation Ebitda
According to the company disclosure, Generation Bio Co reported earnings before interest,tax, depreciation and amortization of (133.3 Million). This is 115.19% lower than that of the Biotechnology sector and 233.09% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.42% higher than that of the company.
Generation EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Generation Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Generation Bio could also be used in its relative valuation, which is a method of valuing Generation Bio by comparing valuation metrics of similar companies.Generation Bio is currently under evaluation in ebitda category among its peers.
Generation Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Generation Bio from analyzing Generation Bio's financial statements. These drivers represent accounts that assess Generation Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Generation Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 772.7M | 398.6M | 228.4M | 262.7M | 249.5M | |
| Enterprise Value | 1.1B | 709.8M | 104.3M | 216.9M | 249.5M | 237.0M |
Generation Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Generation Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Generation Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Generation Bio's value.| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | State Street Corp | 2024-06-30 | 980.5 K | Ubs Group Ag | 2024-06-30 | 837.8 K | Partner Fund Management Lp | 2024-09-30 | 787.9 K | Renaissance Technologies Corp | 2024-09-30 | 594.3 K | Deutsche Bank Ag | 2024-06-30 | 558 K | D. E. Shaw & Co Lp | 2024-06-30 | 487.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 441.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 423.3 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 9.5 M | Fmr Inc | 2024-09-30 | 5.3 M |
Generation Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (2.21) % | ||||
| Current Valuation | (2.82 M) | ||||
| Shares Outstanding | 66.79 M | ||||
| Shares Owned By Insiders | 14.51 % | ||||
| Shares Owned By Institutions | 83.88 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 4.74 X | ||||
| Revenue | 5.9 M | ||||
| EBITDA | (133.3 M) | ||||
| Net Income | (126.61 M) | ||||
| Cash And Equivalents | 301.17 M | ||||
| Cash Per Share | 5.07 X | ||||
| Total Debt | 97.89 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 17.93 X | ||||
| Book Value Per Share | 1.56 X | ||||
| Cash Flow From Operations | (52.74 M) | ||||
| Short Ratio | 17.16 X | ||||
| Earnings Per Share | (2.19) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 174 | ||||
| Beta | 2.82 | ||||
| Market Capitalization | 88.17 M | ||||
| Total Asset | 374.76 M | ||||
| Retained Earnings | (571.38 M) | ||||
| Working Capital | 232.7 M | ||||
| Net Asset | 374.76 M |
About Generation Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Generation Bio Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Generation Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Generation Bio Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Generation Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Generation Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Generation Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Generation Stock
| 0.65 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.83 | ME | 23Andme Holding | PairCorr |
| 0.67 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Generation Stock
| 0.49 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.41 | RNXT | RenovoRx | PairCorr |
| 0.36 | KZR | Kezar Life Sciences | PairCorr |
The ability to find closely correlated positions to Generation Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Generation Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Generation Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Generation Bio Co to buy it.
The correlation of Generation Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Generation Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Generation Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Generation Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Generation Bio Piotroski F Score and Generation Bio Altman Z Score analysis. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.28 | Quarterly Revenue Growth 2.52 | Return On Assets (0.19) | Return On Equity (0.86) |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.